BioNTech is trading 4.85% up now at $116.27, extending the strong August 19, 2026 rally; the move appears driven primarily by investor read-through from Moderna and Merck’s positive cancer-vaccine results, which strengthened sentiment toward mRNA oncology platforms.
- The move follows a 1.97% fall on August 20; BioNTech itself reported no new trial outcome.
- Its August 20 announcement of upcoming lung-cancer presentations includes updated Phase 3 survival data for gotistobart and first global combination data for pumitamig, but no numerical results were reported.